Incyte Corp. closed 18.70% short of its 52-week high of $83.95, which the company achieved on November 8th.

Incyte Corp. closed 16.64% below its 52-week high of $83.95, which the company achieved on November 8th.

Incyte is gearing up to report its fiscal second-quarter earnings later this month, with analysts forecasting a sharp surge ...

The PocketMBA program embodies UD PCS’ commitment to equipping professionals with the skills necessary to excel in dynamic ...

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience ...

Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for ...

Sun Pharma settles litigation with Incyte over Leqselvi, launches product for severe alopecia areata treatment in the US.

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

Sun Pharma settles litigation with Incyte, gains license for alopecia treatment, launches LEQSELVI tablet in the US.

As part of the agreement, Incyte has granted Sun Pharma a limited, non-exclusive license to US Patent Nos. 9,662,335 and ...

Sun Pharmaceutical Industries has reached a settlement with Incyte Corporation regarding the Leqselvi drug, used for severe ...